U.S. Markets closed

3 Healthcare Stocks that Could Move on Industry Growth

CORAL GABLES, FL / ACCESSWIRE / October 30, 2018 / According to the MarketsAndMarkets* report "Healthcare IT Market by Product (EHR, RIS, PACS, VNA, CPOE, HIE, Telehealth, Healthcare Analytics, Population Health Management, Supply Chain Management, CRM, Fraud Management, Claims Management) End User (Provider, Payer) - Global Forecast to 2021", the market for healthcare IT is expected to reach $280.25 Billion by 2021 at a CAGR of 15.9% during the forecast period. This is up significantly from $134.25 Billion in 2016.

The report states that "The majority of the demand for healthcare IT solutions is driven by the growing need to reduce healthcare costs while adhering to the regulatory requirements set by government organizations for ensuring safety, security, and confidentiality of patient information. The growing adoption of health information exchanges (HIEs) and EHR systems and improved quality of care and clinical outcomes are some of the other factors driving market growth."

Following these latest industry trends, companies like Premier Health Group, Inc. ( PHGRF )(PHGI.CN), Achieve Life Sciences, Inc. (ACHV) and Titan Pharmaceuticals, Inc. (TTNP) are in focus on Tuesday.

Premier Health Group, Inc. ( PHGRF )(PHGI.CN) successfully acquired HealthVue Medical Clinics in August. With this acquisition, Premier was able to enter the primary care clinic and healthcare technology business. HealthVue is a group of four Greater Vancouver-based fully integrated, paperless and electronic-medical-record-based medical clinics with a 10-year history, 22 healthcare professionals and over 100,000 active patients. The clinics have seen revenue growth in excess of 25 percent year over year for the past three years and thus far accounted for over 36,000 patient visits in 2018. HealthVue will open its fifth clinic in Q4 2018.

According to a Research And Markets report, the market for telemedicine was valued at $ 29.6 Billion in 2017 and is anticipated to grow at a compounded annual rate of approximately 19% during 2017-2022. The reported growth of the market is likely to be driven by increasing adoption of telemedicine, rising incidences of chronic diseases, growing geriatric population, government initiatives, and a shortage of physicians among others.

Furthermore, Premier Health Group, Inc. ( PHGRF )(PHGI.CN) expansion plans include new clinic openings, acquisitions (clinic, technology, and patients), cannabis clinic(s) and partnerships. Just last week Premier Health Group, Inc. ( PHGRF )(PHGI.CN) announced that its common shares traded on the OTC Markets Group Inc.'s OTCQB Venture Market in the United States, under the symbol PHGRF, are Depository Trust Company eligible, effective Oct. 22, 2018.

For More Information On Premier Health Group, Click Here

Achieve Life Sciences, Inc. (ACHV) is a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation. Today Achieve announced the initiation of a Phase 2b ORCA-1 trial for smoking cessation.

ORCA-1 is the first in Achieve's ORCA (Ongoing Research of Cytisinicline for Addiction) Program, that aims to evaluate the effectiveness of cytisinicline for smoking cessation and potentially other indications. This Phase 2b trial will evaluate both the 1.5mg and 3mg doses of cytisinicline on a declining titration schedule over 25 days, as well as three times daily dosing. The trial is randomized and blinded to compare the effectiveness of the cytisinicline doses and schedules to respective placebo groups. The primary efficacy endpoint is reduction in the number of cigarettes smoked during treatment with secondary analyses conducted on smoking cessation rates, safety, and compliance. ORCA-1 will evaluate approximately 250 smokers and is being conducted at eight centers across the U.S. Data results are expected in mid-2019.

In a corporate release, Rick Stewart, Chairman and Chief Executive Officer of Achieve Life Sciences said, "We intend to utilize our learnings from this trial to finalize the Phase 3 program, expected to begin later next year."

Shares were up sharply during pre-market trading on Tuesday morning.

For More Information On Achieve Life Sciences, Click Here

Titan Pharmaceuticals, Inc. (TTNP) signed a license agreement with Knight Therapeutics (GUD.TO) to distribute PROBUPHINE in Canada. PROBUPHINE is a subdermal implant designed to deliver buprenorphine continuously for 6 months following a single treatment. This morning, Knight announced the commercial availability of PROBUPHINE™ for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support.

"The approval of Probuphine by Health Canada earlier this year was a milestone and we look forward to supporting our partner Knight Therapeutics in this next phase," said Titan President and CEO Sunil Bhonsle. "The commercial launch of Probuphine provides the Canadian medical community with a novel, long-term treatment alternative that can provide benefits to many patients suffering from this disease."

For More Information On Titan Pharmaceuticals, Click Here

What Is Stock Price (StockPrice.com)?

Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.

StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.

At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.

JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2018 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2018 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.

*MarketsAndMarkets Report: https://www.marketsandmarkets.com/PressReleases/healthcare-it-market.asp

Contact Information:

news@stockprice.com

SOURCE: StockPrice.com